Product logins

Find logins to all Clarivate products below.


Overactive Bladder | Treatment Algorithms | Claims Data Analysis | US | 2019

Overactive bladder is a common condition that manifests as a complex set of symptoms in the lower urinary tract and affects both men and women. It is characterized by sudden urges to urinate and may be accompanied by urinary incontinence, urinary frequency, and/or nocturia (nighttime waking to void the bladder). In addition to possible lifestyle changes and/or behavior interventions to help manage overactive bladder, a step-up approach to treatment is generally followed. It typically begins with antimuscarinics, before progressing to more-potent drugs, such as the beta3 adrenergic receptor agonist Myrbetriq (Astellas) or the injectable neurotoxin Botox (Allergan).

QUESTIONS ANSWERED

  •  What patient shares do key therapies and brands garner by line of therapy in newly diagnosed overactive bladder patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed overactive bladder patients?
  •  How have Myrbetriq and Botox been integrated into the treatment algorithm, and what is their source of business?
  • What percentage of overactive bladder patients receive drug therapy within one year of diagnosis and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of overactive bladder patients are treated with monotherapy versus combination therapy? What are the most common combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

CONTENT HIGHLIGHTS

Geographies

United States

Real-world data

Longitudinal patient-level claims data analysis

Key drugs covered

Botox, Myrbetriq, oral oxybutynin, tolterodine tartrate, trospium chloride, Vesicare

Key analysis provided

  • Brand/therapy usage across longitudinal patient sample
  • Newly diagnosed patient analysis
  • Treatment initiation and progression
  • Line of therapy analysis
  • Combination therapy analysis
  • Source of business for recently treated patients
  • Persistency and compliance analysis
  • Product-level patient flowcharts

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Related Market Assessment Reports

Report
Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms: Claims Data Analysis – Immune Thrombocytopenic Purpura (US)
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count, resulting in an increased risk of bleeding. Current therapies for ITP can be largely divided…
Report
Myasthenia Gravis – Geography Focus: China – China In-Depth: Myasthenia Gravis
China’s myasthenia gravis (MG) market is transitioning from long-standing symptomatic regimens toward a more structured mix of targeted therapies that increasingly shape treatment pathways…
Report
Alopecia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alopecia Areata (US)
Alopecia areata (AA) is an autoimmune condition in which the immune-mediated damage to hair follicles results in patchy or extensive hair loss. AA treatment is evolving rapidly as dermatologists…
Report
Psoriatic Arthritis – Unmet Need – Unmet Need – Psoriatic Arthritis (US/EU)
The psoriatic arthritis (PsA) therapy market is on a growth trajectory, fueled by the disease’s increasing prevalence, innovative treatment options, and heightened patient awareness. TNF-alpha…
Report
Chronic Urticaria – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Spontaneous Urticaria (US)
The treatment landscape for chronic spontaneous urticaria (CSU) remains largely driven by oral therapies, including approved antihistamines and off-label agents such as DMARDs and…